AstraZeneca stock falls after FDA panel votes against new cancer drug

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.

Mixed FDA Votes On Truqap And Camizestrant Refocus AstraZeneca Oncology Risk

FDA advisory panel backs AstraZeneca’s Truqap as the first targeted therapy for PTEN deficient metastatic hormone sensitive ...

AstraZeneca’s breast-cancer candidate drug loses FDA panel vote

The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer ...
Fierce Biotech

FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...
Reuters

WHO says its advisory committee looking at AstraZeneca vaccine issues

GENEVA, March 12 (Reuters) - A World Health Organization expert advisory committee is currently looking at AstraZeneca's (AZN.L), opens new tab COVID-19 vaccine after some countries paused ...
BioSpace

AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio

While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also ...
Reuters

AstraZeneca shot is good if safety issues can be overcome, U.S. official Fauci says

LONDON (Reuters) - U.S. infectious disease official Anthony Fauci said AstraZeneca's COVID-19 vaccine had good efficacy, but safety concerns needed to be straightened out and it might not be needed ...
Los Angeles Times

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

This is read by an automated voice. Please report any issues or inconsistencies here. AstraZeneca becomes second major pharmaceutical company to agree to lower Medicaid drug prices under Trump ...
Morningstar

AstraZeneca results: FY and Q4 2025

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 ...